12:00 AM
Apr 13, 2015
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Exviera dasabuvir: Phase IIIb data

The open-label, international Phase IIIb MALACHITE-I trial in 311 treatment-naive patients with chronic HCV genotype 1 infection without cirrhosis showed that Viekirax ombitasvir/paritaprevir/ritonavir and Exviera with and without ribavirin for 12 weeks led to SVR4 rates of 97.1-98.8% vs. 82.9-85.3% for Incivek telaprevir plus peginterferon and ribavirin for 12 weeks followed by peginterferon and ribavirin alone for 12-36 weeks. In patients with HCV genotype 1a infection, Viekirax and Exviera plus ribavirin led...

Read the full 360 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >